UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 14, 2015
PERRIGO COMPANY PLC
(Exact name of registrant as specified in its charter)
Commission file number 001-36353
Ireland | Not Applicable | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland |
Not Applicable | |
(Address of principal executive offices) | (Zip Code) |
+353 1 7094000
(Registrants telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On September 14, 2015, Perrigo Company plc (Perrigo) issued a press release and a memo to employees confirming that Mylan N.V. has commenced an unsolicited exchange offer to acquire all of the outstanding ordinary shares of Perrigo. Copies of the press release and memo to employees are attached hereto as Exhibit 99.1 and Exhibit 99.2 respectively, and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 | Press Release issued by Perrigo Company plc, dated September 14, 2015 | |
Exhibit 99.2 | Memo to Perrigo Company plc Employees |
Signature
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PERRIGO COMPANY PLC | ||||
(Registrant) | ||||
By: | /s/ Todd W. Kingma | |||
Dated: September 14, 2015 | Todd W. Kingma | |||
Executive Vice President, General Counsel and Secretary |
Exhibit Index
Exhibit 99.1 | Press Release issued by Perrigo Company plc, dated September 14, 2015 | |
Exhibit 99.2 | Memo to Perrigo Company plc Employees |
Exhibit 99.1
PERRIGO ANNOUNCEMENT REGARDING UNSOLICITED OFFER FROM MYLAN N.V.
Shareholders Advised to Take NO ACTION Pending Review
DUBLIN September 14, 2015 Perrigo Company plc (Perrigo) (NYSE: PRGO; TASE) today confirmed that Mylan N.V. (Mylan) (NASDAQ: MYL) has commenced an unsolicited exchange offer to acquire all of the issued and to be issued ordinary shares of Perrigo. Shareholders are strongly advised to take no action in relation to the offer at this time pending the Boards review.
The Board of Perrigo will assess Mylans offer and advise Perrigo shareholders of its recommendation regarding the exchange offer within 10 business days by making available to shareholders and filing with the U.S. Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9 and in accordance with Rule 25 of the Irish Takeover Rules. Applicable securities laws restrict Perrigos ability to comment on Mylans offer until after its Schedule 14D-9 has been filed.
Irish Takeover Rules
The directors of Perrigo accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
A person interested in 1% or more of any class of relevant securities of Perrigo or Mylan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013 (Irish Takeover Rules).
A disclosure table, giving details of the companies in whose relevant securities dealings should be disclosed can be found on the Irish Takeover Panels website at www.irishtakeoverpanel.ie. Interests in securities arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an interest by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities. Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panels website.
If you are in any doubt as to whether you are required to disclose a dealing under Rule 8, please consult the Irish Takeover Panels website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020; fax number +353 1 678 9289.
Important Information
Morgan Stanley & Co. LLC acting through its affiliate, Morgan Stanley & Co. International plc, is financial advisor to Perrigo and no one else in connection with the matters referred to in this announcement. In connection with such matters, Morgan Stanley & Co. LLC, Morgan Stanley & Co. International plc, each of their affiliates and each of their and their affiliates respective directors, officers, employees and
agents will not regard any other person as their client, nor will they be responsible to any other person other than Perrigo for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Companys future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, potential or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Companys control, including future actions that may be taken by Mylan in furtherance of its unsolicited proposal. These and other important factors, including those discussed under Risk Factors in the Perrigo Companys Form 10-K for the year ended June 27, 2015, as well as the Companys subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Additional Information and Where to Find It
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. Perrigo intends to file a solicitation/recommendation statement with respect to the exchange offer with the Securities and Exchange Commission (SEC). Security holders are urged to read the solicitation/recommendation statement and other relevant materials if and when they become available because they will contain important information. The solicitation/recommendation statement and other SEC filings made by Perrigo may be obtained (when available) without charge at the SECs website at www.sec.gov and at the investor relations section of the Perrigo website at perrigo.investorroom.com. Shareholders may also obtain copies of the information by contacting Mackenzie Partners, Inc. at 212-929-5500 or 800-322-2885 Toll-Free in North America or by email at PRGO@mackenziepartners.com
About Perrigo
Perrigo Company plc, a top five global over-the-counter (OTC) consumer goods and pharmaceutical company, offers consumers and customers high quality products at affordable prices. From its beginnings in 1887 as a packager of generic home remedies, Perrigo, headquartered in Ireland, has grown to become the worlds largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies primarily in North America, Europe, and Australia, as well as other key markets including Israel and China.
A copy of this announcement will be available on Perrigos website at www.perrigo.com.
For further information:
Arthur J. Shannon, Vice President, Investor Relations and Global Communications, (269) 686-1709, ajshannon@perrigo.com
Bradley Joseph, Director, Investor Relations and Global Communications, (269) 686-3373, bradley.joseph@perrigo.com
Exhibit 99.2
Dear Perrigo Colleagues,
Earlier today and as expected, Mylan N.V. commenced its unsolicited exchange offer, known as a tender offer, to acquire the Perrigo Company.
While, you may see this in the news, I wanted to give you some insight into the next steps in our process:
| Perrigos Board of Directors will meet and assess Mylans offer. |
| Then, in the coming days, the Board will advise Perrigo shareholders of its recommendation through a formal filing, known as a 14D-9, with the Securities and Exchange Commission (SEC). |
| In the meantime, we have strongly advised our shareholders to take no action in relation to Mylans tender offer pending the Boards review. |
Given the disclosure restrictions we operate under as a publicly traded company that is the subject of a tender offer and to the Irish Takeover Rules, we are restricted in what we can say about Mylans tender offer until the company has filed its official recommendation statement with the SEC, which will also constitute our response document for Irish Takeover Rules purposes. We will be able to provide more information on Mylans offer once the 14D-9 is filed and this quiet period is over.
As always, I am grateful for your hard work. Your contributions to Perrigo make us an exceptional company, and it is important that we continue to conduct business as usual, execute on our goals, and deliver on our promise to provide high Quality Affordable Healthcare Products® to consumers and patients worldwide.
If you have any questions or concerns once the quiet period is over, please reach out to your manager or HR representative.
Joe Papa
Chairman & CEO
Additional Information and Where to Find It
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. Perrigo intends to file a solicitation/recommendation statement with respect to the exchange offer with the Securities and Exchange Commission (SEC). Security holders are urged to read the solicitation/recommendation statement and other relevant materials if and when they become available because they will contain important information. The solicitation/recommendation statement and other SEC filings made by Perrigo may be obtained (when available) without charge at the SECs website at www.sec.gov and at the investor relations section of the Perrigo website at perrigo.investorroom.com. Shareholders may also obtain copies of the information by contacting Mackenzie Partners, Inc. at 212-929-5500 or 800-322-2885 Toll-Free in North America or by email at PRGO@mackenziepartners.com.
Irish Takeover Rules
The directors of Perrigo accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Perrigo (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
A person interested in 1% or more of any class of relevant securities of Perrigo or Mylan may have disclosure obligations under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2013 (Irish Takeover Rules).
No statement in this communication is intended to constitute a profit forecast for any period, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods. No statement in this communication constitutes an asset valuation.
D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&I_$+1[3PEXB:9=*NVCF:;4C#,89?)MPAGDV2 ABL9V\$X!!/PO\ \%B[
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MLJ\Z.'BY\K:T3O9.UVNAHJT5!2J-*_F?2]%?+!_X+6_LPKIZW/\ PM.S,;=
M-'U$R?\ ?'V?>F1S4UG?^BC7I_AGQO_P43^('
MPWTW2?#6E:WI7AFYTBS966EV>VS,*)&8[F3$JG9M(82!QG((QQYA_P<%_
M\I'-8_[ >G?^BC7[:?LP\_LU?#S_ +%G3?\ TECK]$S#'K"Y9A9.G&=U]I7M
MHMCP:%#VN)JKF:UZ.Q^4W[-O_!%W7/A%9Z[\;OVDYHI],\'VMSXGN_#,-VNI
M7NL20!YW%W-DQ$,4SL5Y/-WX9DY!\"_9IU'1/^"FG[?MYXD_:%\?:5X>\/"V
MEU6[%]JT>F6TL4QD'[-?\%-_"%WXY_X)_P#Q
M
D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0, PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#044%]@8&!A8&)P8W!D@&
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M',P<]1T>'4<=:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A( &YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&